University of Colorado Cancer Center

 

Insights from 2024 EHA Annual Meeting
M

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - Analyzing Therapy Lines and BTKi Response

By Insights from 2024 EHA Annual Meeting FEATURING Manali Kamdar
By Insights from 2024 EHA Annual Meeting FEATURING Manali Kamdar
20 views
June 20, 2024
0 Comments
Login to view comments. Click here to Login
Videos
08:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "TRANSFORM Study - 3-Year Follow-up Compar…

Feat. M. Kamdar
07:38
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - A…

Feat. M. Kamdar
39:44
University of Colorado Cancer Center

Understanding Immune Fitness and Age to Improve Breast Cancer Outcom…

Feat. S. Mcallister
44:36
University of Colorado Cancer Center

Type 2 Diabetes Risk With Endocrine Therapies for Breast Cancer

Feat. R. Scalzo
10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
13:36
University of Colorado Cancer Center

Colorectal Surgery for Lynch Syndrome

Feat. J. Vogel
15:33
University of Colorado Cancer Center

Treatment Options for Patients With Lynch Syndrome & CRC

Feat. C. Lieu
41:30
University of Colorado Cancer Center

Lynch Syndrome: The Past, the Present, and the Future

Feat. P. Lynch
46:03
University of Colorado Cancer Center

CAR NK Cells: Next Generation Cell Therapies for Cancer

Feat. K. Rezvani
14:52
University of Colorado Cancer Center

Efforts to Understand Metastatic Drivers of Acral Melanoma

Feat. V. Rebecca
22:23
University of Colorado Cancer Center

Delineating the Therapy Resistance Landscape of Acral Melanoma

Feat. V. Rebecca
07:25
Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "The Use of Rucaparib vs. Placebo Maintenanc…

Feat. B. Corr
11:43
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Selection of Bispecific Antibody Therapies …

Feat. M. Kamdar
07:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Re…

Feat. M. Amaya
14:59
University of Colorado Cancer Center

EGFR Exon 20 Insertion Mutations in NSCLC: Optimal and “Soon to Be O…

Feat. T. Patil
11:37
Insights from 2023 ASCO® Annual Meeting

Assessment and Decision Tools for Balancing Survival and Quality of …

Feat. E. Kessler
21:12
University of Colorado Cancer Center

Current 1L Approaches to ALK and ROS1 NSCLC

Feat. T. Patil
09:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Effect of CBM588 in Combination With Cabo…

Feat. H. Ebrahimi
05:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Updated Results for Cohort H of EV-103 Tr…

Feat. T. Flaig
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar
03:26
PrecisCa

The BRUIN Study: Pirtobrutinib in Mantle Cell Lymphoma

Feat. M. Kamdar
07:47
PrecisCa

Treatment Approach for Older Patients With Mantle Cell Lymphoma: A D…

Feat. M. Kamdar
02:52
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of …

Feat. M. Amaya
03:33
PrecisCa

Mosunetuzumab in R/R Follicular Lymphoma

Feat. M. Kamdar
02:53
PrecisCa

The POLARIX Trial: Polatuzumab With R-CHP in DLBCL

Feat. M. Kamdar
06:28
PrecisCa

Updates From the ECHELON-1 Trial Utilizing Brentuximab in Hodgkin’s …

Feat. M. Kamdar
18:33
Total Health

Sexual & Marital Dysfunction in Women With Gynecologic Cancer

Feat. S. Guntupalli
21:35
Total Health

Management of Advanced NSCLC: IO, Targeted Therapy, and Beyond

Feat. T. Patil
22:52
Total Health

Breast Cancer Genetics, Genomics, and Emerging Diagnostic Tools

Feat. R. Acharya-Leon
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
19:23
University of Colorado Cancer Center

Evolving Paradigms in the Management of Early-Stage NSCLC

Feat. T. Patil
12:42
University of Colorado Cancer Center

Management of Patients With R/R MCL

Feat. M. Kamdar
40:59
University of Colorado Cancer Center

Cancer 'Super-Survivors': ALK+ NSCLC

Feat. R. Camidge
04:56
University of Colorado Cancer Center

Liso-Cel CAR T-Cell Therapy vs. Salvage Chemo Followed by ASCT as 2L…

Feat. M. Kamdar
08:29
University of Colorado Cancer Center

Application and Development of ctDNA in Early Stage CRC

Feat. C. Lieu
07:12
i3 Health

New Opportunities in Advanced KRAS Mutation-Positive NSCLC: Biomarke…

Feat. R. Camidge, B. Sandy
11:24
University of Colorado Cancer Center

Practical Principles of Biomarker Testing in aNSCLC: FDA Approved Th…

Feat. T. Patil
15:14
University of Colorado Cancer Center

Practical Principles of Biomarker Testing in aNSCLC: Overview of Cur…

Feat. T. Patil
09:54
University of Colorado Cancer Center

Targeting mNSCLC: Alectinib & Crizotinib, Chemoimmunotherapy in …

Feat. T. Patil
06:46
University of Colorado Cancer Center

KRAS-G12V-Mutant NSCLC: Is There Any Benefit With RAF/MEK Inhibitor …

Feat. R. Camidge
14:33
University of Colorado Cancer Center

KRAS-Mutated NSCLC Update: Are We Close to a Highly-Effective Target…

Feat. J. Pacheco
20:06
University of Colorado Cancer Center

How I Treat Lung Cancer in 2020: Major Risk Factors & Death Rate…

Feat. T. Patil
10:45
University of Colorado Cancer Center

How I Treat Early NSCLC in 2020: How Critical Is Lymph Node Determin…

Feat. T. Patil
09:29
University of Colorado Cancer Center

mNSCLC Treatment: How Critical Is Molecular Profiling for Targeted T…

Feat. T. Patil
15:28
University of Colorado Cancer Center

ES-SCLC Paradigm Change Following IMpower133 and CASPIAN Trials: Wha…

Feat. J. Pacheco
25:36
University of Colorado Cancer Center

Brigatinib vs Crizotinib in Advanced ALK+ NSCLC: A Glimpse Into the …

Feat. R. Camidge